Literature DB >> 7820139

Vascular considerations in postchemotherapy. Retroperitoneal lymph-node dissection: Part II.

J P Donohue1, J A Thornhill, R S Foster, R Bihrle.   

Abstract

A total of 710 patients underwent postchemotherapy retroperitoneal lymph-node dissection (RPLND) from 1965 to 1992. Ten patients, all with bulky disease, required aortic replacement either postoperatively (n = 3) or during RPLND (n = 7). The principal risk factor for aortic rupture after RPLND was an extended subadventitial aortic dissection made necessary by tumor fixation. Also, duodenal enterotomy or extensive violation of the bowel serosa was a further risk for aortoenteric fistula. Prospective aortic grafting may be indicated in the presence of these risk factors. In our four elective cases, there was no further vascular or bowel complication. Omental interposition further protects against fistula formation. Although rarely indicated except under the most extenuating circumstances, the exposure requirements of RPLND permit aortic grafting as a relatively straightforward procedure that is feasible and well tolerated in this small subset of patients.

Entities:  

Mesh:

Year:  1994        PMID: 7820139     DOI: 10.1007/BF00185669

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  9 in total

1.  Reassessment of the role of adjunctive surgical therapy in the treatment of advanced germ cell tumors.

Authors:  G E Carter; G Lieskovsky; D G Skinner; J R Daniels
Journal:  J Urol       Date:  1987-12       Impact factor: 7.450

2.  Complications of transabdominal retroperitoneal lymphadenectomy.

Authors:  R J Babaian; R B Bracken; D E Johnson
Journal:  Urology       Date:  1981-02       Impact factor: 2.649

3.  Cytoreductive surgery for metastatic testis cancer: tissue analysis of retroperitoneal masses after chemotherapy.

Authors:  J P Donohue; L M Roth; J M Zachary; R G Rowland; L H Einhorn; S G Williams
Journal:  J Urol       Date:  1982-06       Impact factor: 7.450

4.  Complications of thoracoabdominal retroperitoneal lymph node dissection.

Authors:  D G Skinner; A Melamud; G Lieskovsky
Journal:  J Urol       Date:  1982-06       Impact factor: 7.450

5.  Retroperitoneal lymphadenectomy: the anterior approach including bilateral suprarenal-hilar dissection.

Authors:  J P Donohue
Journal:  Urol Clin North Am       Date:  1977-10       Impact factor: 2.241

6.  Risk/benefit of treating retroperitoneal teratoid bulky tumors.

Authors:  N Jaeger; L Weissbach; J H Hartlapp; W Vahlensieck
Journal:  Urology       Date:  1989-07       Impact factor: 2.649

7.  Multivariate analysis of prognostic variables in patients with metastatic testicular cancer.

Authors:  G J Bosl; N L Geller; C Cirrincione; N J Vogelzang; B J Kennedy; W F Whitmore; D Vugrin; H Scher; J Nisselbaum; R B Golbey
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

8.  En bloc resection of inferior vena cava in cytoreductive surgery for bulky retroperitoneal metastatic testicular cancer.

Authors:  D J Mathisen; N Javadpour
Journal:  Urology       Date:  1980-07       Impact factor: 2.649

9.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

  9 in total
  1 in total

1.  A meta-analysis of clinicopathologic features that predict necrosis or fibrosis at post-chemotherapy retroperitoneal lymph node dissection in individuals receiving treatment for non-seminoma germ cell tumours.

Authors:  Ciara Conduit; Wei Hong; Felicity Martin; Benjamin Thomas; Nathan Lawrentschuk; Jeremy Goad; Peter Grimison; Nariman Ahmadi; Ben Tran; Jeremy Lewin
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.